Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Cegielski is active.

Publication


Featured researches published by Peter Cegielski.


The Lancet | 2012

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Tracy Dalton; Peter Cegielski; Somsak Akksilp; Luis Asencios; Janice Campos Caoili; Sang-Nae Cho; Vladislav V. Erokhin; Julia Ershova; Ma Tarcela Gler; Boris Y. Kazennyy; Hee Jin Kim; Kai Kliiman; Ekaterina V. Kurbatova; Charlotte Kvasnovsky; Vaira Leimane; Martie van der Walt; Laura E. Via; Grigory V. Volchenkov; Martin Yagui; Hyungseok Kang

BACKGROUND The prevalence of extensively drug-resistant (XDR) tuberculosis is increasing due to the expanded use of second-line drugs in people with multidrug-resistant (MDR) disease. We prospectively assessed resistance to second-line antituberculosis drugs in eight countries. METHODS From Jan 1, 2005, to Dec 31, 2008, we enrolled consecutive adults with locally confirmed pulmonary MDR tuberculosis at the start of second-line treatment in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea, and Thailand. Drug-susceptibility testing for study purposes was done centrally at the Centers for Disease Control and Prevention for 11 first-line and second-line drugs. We compared the results with clinical and epidemiological data to identify risk factors for resistance to second-line drugs and XDR tuberculosis. FINDINGS Among 1278 patients, 43·7% showed resistance to at least one second-line drug, 20·0% to at least one second-line injectable drug, and 12·9% to at least one fluoroquinolone. 6·7% of patients had XDR tuberculosis (range across study sites 0·8-15·2%). Previous treatment with second-line drugs was consistently the strongest risk factor for resistance to these drugs, which increased the risk of XDR tuberculosis by more than four times. Fluoroquinolone resistance and XDR tuberculosis were more frequent in women than in men. Unemployment, alcohol abuse, and smoking were associated with resistance to second-line injectable drugs across countries. Other risk factors differed between drugs and countries. INTERPRETATION Previous treatment with second-line drugs is a strong, consistent risk factor for resistance to these drugs, including XDR tuberculosis. Representative drug-susceptibility results could guide in-country policies for laboratory capacity and diagnostic strategies. FUNDING US Agency for International Development, Centers for Disease Control and Prevention, National Institutes of Health/National Institute of Allergy and Infectious Diseases, and Korean Ministry of Health and Welfare.


Emerging Infectious Diseases | 2008

Scale-up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru

Sonya Shin; Martin Yagui; Luis Ascencios; Gloria Yale; Carmen Suarez; Neyda Quispe; Cesar Bonilla; Joaquin Blaya; Allison Taylor; Carmen Contreras; Peter Cegielski

One-sentence summary for table of contents: Strategic design and implementation of these services is feasible in resource-poor settings.


Lancet Infectious Diseases | 2017

Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study

Aditya Sharma; Andrew N. Hill; Ekaterina V. Kurbatova; Martie van der Walt; Charlotte Kvasnovsky; Thelma E. Tupasi; Janice Campos Caoili; Maria Tarcela Gler; Grigory V. Volchenkov; Boris Y. Kazennyy; Olga V. Demikhova; Jaime Bayona; Carmen Contreras; Martin Yagui; Vaira Leimane; Sang-Nae Cho; Hee Jin Kim; Kai Kliiman; Somsak Akksilp; Ruwen Jou; Julia Ershova; Tracy Dalton; Peter Cegielski

BACKGROUND Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries. We used estimates from the Preserving Effective TB Treatment Study to predict MDR and XDR tuberculosis trends in four countries with a high burden of MDR tuberculosis: India, the Philippines, Russia, and South Africa. METHODS We calibrated a compartmental model to data from drug resistance surveys and WHO tuberculosis reports to forecast estimates of incident MDR and XDR tuberculosis and the percentage of incident MDR and XDR tuberculosis caused by acquired drug resistance, assuming no fitness cost of resistance from 2000 to 2040 in India, the Philippines, Russia, and South Africa. FINDINGS The model forecasted the percentage of MDR tuberculosis among incident cases of tuberculosis to increase, reaching 12·4% (95% prediction interval 9·4-16·2) in India, 8·9% (4·5-11·7) in the Philippines, 32·5% (27·0-35·8) in Russia, and 5·7% (3·0-7·6) in South Africa in 2040. It also predicted the percentage of XDR tuberculosis among incident MDR tuberculosis to increase, reaching 8·9% (95% prediction interval 5·1-12·9) in India, 9·0% (4·0-14·7) in the Philippines, 9·0% (4·8-14·2) in Russia, and 8·5% (2·5-14·7) in South Africa in 2040. Acquired drug resistance would cause less than 30% of incident MDR tuberculosis during 2000-40. Acquired drug resistance caused 80% of incident XDR tuberculosis in 2000, but this estimate would decrease to less than 50% by 2040. INTERPRETATION MDR and XDR tuberculosis were forecast to increase in all four countries despite improvements in acquired drug resistance shown by the Green Light Committee-supported programmatic management of drug-resistant tuberculosis. Additional control efforts beyond improving acquired drug resistance rates are needed to stop the spread of MDR and XDR tuberculosis in countries with a high burden of MDR tuberculosis. FUNDING US Agency for International Development and US Centers for Disease Control and Prevention, Division of Tuberculosis Elimination.


Emerging Infectious Diseases | 2012

Challenges and controversies in defining totally drug-resistant tuberculosis.

Peter Cegielski; Paul Nunn; Ekaterina V. Kurbatova; Karin Weyer; Tracy Dalton; Douglas F. Wares; Michael F. Iademarco; Kenneth G. Castro; Mario Raviglione

In March 2012, in response to reports of tuberculosis (TB) resistant to all anti-TB drugs, the World Health Organization convened an expert consultation that identified issues to be resolved before defining a new category of highly drug-resistant TB. Proposed definitions are ambiguous, and extensive drug resistance is encompassed by the already defined extensively drug-resistant (XDR) TB. There is no evidence that proposed totally resistant TB differs from strains encompassed by XDR TB. Susceptibility tests for several drugs are poorly reproducible. Few laboratories can test all drugs, and there is no consensus list of all anti-TB drugs. Many drugs are used off-label for highly drug resistant TB, and new drugs formulated to combat resistant strains would render the proposed category obsolete. Labeling TB strains as totally drug resistant might lead providers to think infected patients are untreatable. These challenges must be addressed before defining a new category for highly drug-resistant TB.


Epidemiology and Infection | 2011

Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting.

Hsien-Ho Lin; Sonya Shin; J. A. Blaya; Zibiao Zhang; Peter Cegielski; Carmen Contreras; Luis Asencios; Cesar Bonilla; Jaime Bayona; Christopher J. Paciorek; Ted Cohen

We examined the spatiotemporal distribution of laboratory-confirmed multidrug-resistant tuberculosis (MDR TB) cases and that of other TB cases in Lima, Peru with the aim of identifying mechanisms responsible for the rise of MDR TB in an urban setting. All incident cases of TB in two districts of Lima, Peru during 2005-2007 were included. The spatiotemporal distributions of MDR cases and other TB cases were compared with Ripleys K statistic. Of 11,711 notified cases, 1187 received drug susceptibility testing and 376 were found to be MDR. Spatial aggregation of patients with confirmed MDR disease appeared similar to that of other patients in 2005 and 2006; however, in 2007, cases with confirmed MDR disease were found to be more tightly grouped. Subgroup analysis suggests the appearance of resistance may be driven by increased transmission. Interventions should aim to reduce the infectious duration for those with drug-resistant disease and improve infection control.


Lancet Infectious Diseases | 2015

Tuberculosis and vitamin D: what's the rest of the story?

Peter Cegielski; Andrew Vernon

Both protein–energy undernutrition and specific micronutrient deficiencies debilitate the cell-mediated immune system important in protection against tuberculosis.1 However, once tuberculosis de velops, the disease itself induces a catabolic state resulting in negative nitrogen balance and micronutrient deficiencies. Generations of clinicians treating patients with tuberculosis believed that nutritional support was crucial to proper patient care. Why, then, has it been so difficult to prove through randomised controlled clinical trials that nutritional interventions improve tuberculosis treatment outcomes? Findings from systematic reviews2–6 have not shown any clear, consistent benefit in terms of tuberculosis-specific outcomes, although they do show improvements in nutritional status.


PLOS ONE | 2014

Reducing Communication Delays and Improving Quality of Care with a Tuberculosis Laboratory Information System in Resource Poor Environments: A Cluster Randomized Controlled Trial

Joaquin Blaya; Sonya Shin; Martin Yagui; Carmen Contreras; Peter Cegielski; Gloria Yale; Carmen Suarez; Luis Asencios; Jaime Bayona; Jihoon Kim; Hamish S. F. Fraser

Background Lost, delayed or incorrect laboratory results are associated with delays in initiating treatment. Delays in treatment for Multi-Drug Resistant Tuberculosis (MDR-TB) can worsen patient outcomes and increase transmission. The objective of this study was to evaluate the impact of a laboratory information system in reducing delays and the time for MDR-TB patients to culture convert (stop transmitting). Methods Setting: 78 primary Health Centers (HCs) in Lima, Peru. Participants lived within the catchment area of participating HCs and had at least one MDR-TB risk factor. The study design was a cluster randomized controlled trial with baseline data. The intervention was the e-Chasqui web-based laboratory information system. Main outcome measures were: times to communicate a result; to start or change a patients treatment; and for that patient to culture convert. Results 1671 patients were enrolled. Intervention HCs took significantly less time to receive drug susceptibility test (DST) (median 11 vs. 17 days, Hazard Ratio 0.67 [0.62–0.72]) and culture (5 vs. 8 days, 0.68 [0.65–0.72]) results. The time to treatment was not significantly different, but patients in intervention HCs took 16 days (20%) less time to culture convert (p = 0.047). Conclusions The eChasqui system reduced the time to communicate results between laboratories and HCs and time to culture conversion. It is now used in over 259 HCs covering 4.1 million people. This is the first randomized controlled trial of a laboratory information system in a developing country for any disease and the only study worldwide to show clinical impact of such a system. Trial Registration ClinicalTrials.gov NCT01201941


American Journal of Tropical Medicine and Hygiene | 2013

Weight gain and response to treatment for multidrug-resistant tuberculosis.

Ma Tarcela Gler; Ruffy Guilatco; Janice C. Caoili; Julia Ershova; Peter Cegielski; John L. Johnson

Alternatives to culture are needed in high burden countries to assess whether response to treatment of multidrug-resistant-tuberculosis (MDR-TB) is satisfactory. The objective was to assess the association of weight gain and treatment outcome. The methods included analysis of clinical, bacteriologic, and weight from 439 MDR-TB patients in the Philippines. Odds ratios (ORs) were calculated to determine whether 5% weight gain during the first 6 months of treatment was associated with outcome. Three hundred and ten (71%) patients were cured and 129 (29%) had poor outcomes (death, defaulted, or failed treatment). Fifty-three percent were underweight (body mass index [BMI] < 18.5 kg/m(2)) before treatment. Five percent weight gain after completing 3 months of treatment was associated with good outcome among patients who were underweight before treatment (OR 2.1; 95% confidence interval [CI], 1.05 to 4.4). Baseline weight and degree of weight change during the first 6 months of treatment can help identify persons who are more likely to have poor outcomes and require other interventions.


The Lancet Respiratory Medicine | 2018

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis

Federica Fregonese; Shama D. Ahuja; Onno W. Akkerman; Denise Arakaki-Sanchez; Irene Ayakaka; Parvaneh Baghaei; Didi Bang; Mayara L. Bastos; Andrea Benedetti; Maryline Bonnet; Adithya Cattamanchi; Peter Cegielski; Jung Yien Chien; Helen Cox; Martin Dedicoat; Connie Erkens; Patricio Escalante; Dennis Falzon; Anthony J. Garcia-Prats; Medea Gegia; Stephen H. Gillespie; Judith R. Glynn; Stefan Goldberg; David Griffith; Karen R. Jacobson; James C. Johnston; Edward C. Jones-López; Awal Khan; Won Jung Koh; Afranio Lineu Kritski

BACKGROUND Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ. METHODS Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studies were identified from two relevant systematic reviews, an updated search of one of the systematic reviews (for papers published between April 1, 2015, and Feb 10, 2016), and personal communications. Individual patient data were obtained from authors of eligible studies. The individual patient data meta-analysis was performed with propensity score matched logistic regression to estimate adjusted odds ratios (aOR) and risk differences of treatment success (cure or treatment completion), death during treatment, and acquired rifampicin resistance. Outcomes were measured across different treatment regimens to assess the effects of: different durations of REZ (≤6 months vs >6 months); addition of a fluoroquinolone to REZ (fluoroquinolone plus 6 months or more of REZ vs 6 months or more of REZ); and addition of streptomycin to REZ (streptomycin plus 6 months of rifampicin and ethambutol and 1-3 months of pyrazinamide vs 6 months or more of REZ). The overall quality of the evidence was assessed using GRADE methodology. FINDINGS Individual patient data were requested for 57 cohort studies and 17 randomised trials including 8089 patients with INH-R tuberculosis. We received 33 datasets with 6424 patients, of which 3923 patients in 23 studies received regimens related to the study objectives. Compared with a daily regimen of 6 months of (H)REZ (REZ with or without isoniazid), extending the duration to 8-9 months had similar outcomes; as such, 6 months or more of (H)REZ was used for subsequent comparisons. Addition of a fluoroquinolone to 6 months or more of (H)REZ was associated with significantly greater treatment success (aOR 2·8, 95% CI 1·1-7·3), but no significant effect on mortality (aOR 0·7, 0·4-1·1) or acquired rifampicin resistance (aOR 0·1, 0·0-1·2). Compared with 6 months or more of (H)REZ, the standardised retreatment regimen (2 months of streptomycin, 3 months of pyrazinamide, and 8 months of isoniazid, rifampicin, and ethambutol) was associated with significantly worse treatment success (aOR 0·4, 0·2-0·7). The quality of the evidence was very low for all outcomes and treatment regimens assessed, owing to the observational nature of most of the data, the diverse settings, and the imprecision of estimates. INTERPRETATION In patients with INH-R tuberculosis, compared with treatment with at least 6 months of daily REZ, addition of a fluoroquinolone was associated with better treatment success, whereas addition of streptomycin was associated with less treatment success; however, the quality of the evidence was very low. These results support the conduct of randomised trials to identify the optimum regimen for this important and common form of drug-resistant tuberculosis. FUNDING World Health Organization and Canadian Institutes of Health Research.


International Journal of Epidemiology | 2010

A consistent log-linear relationship between tuberculosis incidence and body mass index

Knut Lönnroth; Brian Williams; Peter Cegielski; Christopher Dye

Collaboration


Dive into the Peter Cegielski's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sonya Shin

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Gloria Yale

Defense Information Systems Agency

View shared research outputs
Top Co-Authors

Avatar

Martin Yagui

National University of San Marcos

View shared research outputs
Top Co-Authors

Avatar

Carmen Suarez

Defense Information Systems Agency

View shared research outputs
Top Co-Authors

Avatar

Joaquin Blaya

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Ekaterina V. Kurbatova

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Julia Ershova

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Tracy Dalton

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge